Immunopharmacology of Vasculitic Syndromes

  • P. A. Bacon
  • R. A. Luqmani
  • D. G. I. Scott
  • D. Adu


The first descriptions of vasculitis were by Kussmaul and Maier in 1866. It may affect any vessel and occur de novo or complicate preexisting diseases. Essentially it can be defined as an inflammation of blood vessels. Vasculitis is an important component of the pathology of connective tissue diseases; Bywaters (1976) hypothesized that vascular inflammation was the basis of connective tissue disease.


Kawasaki Disease Plasma Exchange Giant Cell Arteritis Systemic Vasculitis Polymyalgia Rheumatica 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abdou, N. I., Zweimann, B., and Casella, S. R., 1973, The effects of azathioprine therapy on bone marrow dependent and thymus dependent cells in man, Clin. Exp. Immunol. 13:55–64.PubMedGoogle Scholar
  2. Adu, D., Howie, A. J., Scott, D. G. I., Bacon, P. A., McGonigle, R. J. S., and Michael, J., 1987, Polyarteritis and the kidney, Q. J. Med. 62:221–237.PubMedGoogle Scholar
  3. Allen, C., Elson, C. J., Scott, D. G. I., Bacon, P. A., and Bucknall, R. C., 1981, IgG antiglobulins in rheumatoid arthritis and other arthritides: Relationship with clinical features and other parameters, Ann. Rheum. Dis. 40:127–131.PubMedCrossRefGoogle Scholar
  4. Allison, M. C., and Gallagher, P. J., 1984, Temporal artery biopsy and corticosteroid treatment, Ann. Rheum. Dis. 43:416–417.PubMedCrossRefGoogle Scholar
  5. Anderson, C. L., and Stravides, A., 1978, Rapidly progressive renal failure as the primary manifestation of Wegener’s granulomatosis, Am. J. Med. Sci. 275:109–112.PubMedCrossRefGoogle Scholar
  6. Andersson, R., Jonsson, R., Tarkowski, A., Begtsson, B.-A., and Malmvall, B.-E., 1987, T cell subsets and expression of immunological activation markers in the arterial walls of patients with giant cell arteritis, Ann. Rheum. Dis. 46:915–923.PubMedCrossRefGoogle Scholar
  7. Austin, H. A., Klippel, J. H., Balow, J. E., le Riche, N. G., Steinberg, A. D., Plotz, P. H., and Decker, J. L., 1986, Therapy of lupus nephritis: Controlled trial of prednisolone and cytotoxic drugs, N. EngL J. Med. 314:614–619.PubMedCrossRefGoogle Scholar
  8. Axelson, J. A., Clark, R. H., and Ancerewicz, S., 1987, Wegener’s granulomatosis and trimethoprim-sulphamethoxazole, Ann. Intern. Med. 107:600.PubMedCrossRefGoogle Scholar
  9. Bacon, P. A., 1979, Circulating immune complexes in systemic rheumatoid disease, Rheum. Rehab. (Suppl.)18:11–15.CrossRefGoogle Scholar
  10. Bacon, P. A., 1987, Vasculitis—clinical aspects and therapy, Acta Med. Scand. (Suppl.) 715:157–163.Google Scholar
  11. Baggenstoss, A. H., Shick, R. M., and Polley, H. E., 1950, The effect of cortisone on the lesions of periarteritis nodosa, Am. J. Pathol. 27:537–591.Google Scholar
  12. Baker, G. L., Kahl, L. E., Zee, B. C., Stolzer, B. L., Agarwal, A. K., and Medsger, T. A., 1987, Malignancy following the treatment of rheumatoid arthritis with cyclophosphamide. Long-term cases control follow-up study, Am. J. Med. 83:1–9.PubMedCrossRefGoogle Scholar
  13. Ball, J., 1954, Rheumatoid arthritis and polyarteritis nodosa, Ann. Rheum. Dis. 13:277–290.PubMedCrossRefGoogle Scholar
  14. Behçet, H., 1937, Uber rezidivierende. Aphthose durch ein Virus versuachte Geschgwurec am Mund, am Auge und an den Genitalien, Dermatol Wochenschr. 105:1152–1157.Google Scholar
  15. Borleffs, J. C., Derksen, R. H., and Hene, R. J., 1987, Treatment of Wegener’s granulomatosis with cyclosporin (letter), Ann. Rheum. Dis. 46:175.PubMedCrossRefGoogle Scholar
  16. Bradley, J. D., Brandt, K. D., and Katz, B. P., 1989, Infectious complications of cyclophosphamide treatment for vasculitis, Art/iritis Rheum. 32:45–53.CrossRefGoogle Scholar
  17. Bruce, W., 1888, Senile rheumatic gout, Br. Med. J. 2:811–313.PubMedCrossRefGoogle Scholar
  18. Bywaters, E. G. L., 1976, Vasculitis in rheumatoid arthritis, in: Non-articular Forms of Rheumatoid Arthritis (T. E. W. Feltkamp, ed.), Proceedings of the IV ISRA Symposium, Stafleu’s Scientific Publications, Leiden, pp. 82–84.Google Scholar
  19. Calabrese, L. H., and Mallek, J. A., 1987, Primary angiitis of the central nervous system, Medicine (Baltimore) 67:20–39.Google Scholar
  20. Carrington, C. B., and Liebow, A. A., 1966, Limited forms of angiitis and granulomatosis of Wegener’s type, Am. J. Med. 41:497–527.PubMedCrossRefGoogle Scholar
  21. Chumbley, L. C., Harrison, R. A., and DeRemee, R. A., 1977, Allergic granulomatous angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases, Mayo Clin. Proc. 52:477–484.PubMedGoogle Scholar
  22. Churg, J., and Strauss, L., 1957, Allergic granulomatosis, allergic angiitis, and periarteritis nodosa, Am. J. Pathol 27:277–301.Google Scholar
  23. Cochrane, C. G., 1968, Immunologie tissue injury mediated by neutrophilic leukocytes, Adv. Immunol 9:97–162.PubMedCrossRefGoogle Scholar
  24. Cochrane, C. G., and Aikin, B. S., 1966, Polymorphonuclear leukocytes in immunologic reactions. The destruction of vascular basement membrane in vivo and in vitro, J. Exp. Med. 124:733–752.PubMedCrossRefGoogle Scholar
  25. Cravioto, H., and Feigin, I., 1959, Noninfectious granulomatous angiitis with a predilection for the nervous system, Neurobgy 9:599–609.Google Scholar
  26. Dasgupta, B., Duke, O., Timms, A., Pitzalis, C., and Panayi, G. S., 1989, Selective depletion and activation of CD 8+ lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis, Ann. Rheum. Dis. 48:307–311.PubMedCrossRefGoogle Scholar
  27. Davson, J., Ball, J., and Platt, R., 1948, The kidney in periarteritis nodosa, Q. J. Med. 17:175–202.PubMedGoogle Scholar
  28. Delecoeuillerie, G., Joly, P., Cohen de Lara, A., and Paolaggi, J. B., 1988, Polymyalgia rheumatica and temporal arteritis: A retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients), Ann. Rheum. Dis. 47:733–739.PubMedCrossRefGoogle Scholar
  29. DeRemee, R. A., McDonald, T. J., and Weiland, L. H., 1985, Wegener’s granulomatosis: Observations on treatment with antimicrobial agents, Mayo Clin. Proc. 60:27–32.CrossRefGoogle Scholar
  30. De Silva, M., and Hazelman, B. L., 1986, Azathioprine in giant cell arteritis/polymyalgia rheumatica in a double blind study, Ann. Rheum. Dis. 45:136–138.PubMedCrossRefGoogle Scholar
  31. Drath, D. B., and Kahan, B. D, 1984, Phagocytic cell function in response to immunosuppressive therapy, Arch. Surg. 119:156–160.PubMedCrossRefGoogle Scholar
  32. Droz, D, Noel, L. H., Leibowitch, M., and Barbanel, C., 1979, Glomerulonephritis and necrotizing angiitis, in: Advanced Nephrobgy, Volume 8, Year Book Medical Publishers, Chicago, pp. 343–363.Google Scholar
  33. Dwosh, I. L., Giles, A. R., Ford, P. M., Pater, J. L., Anastassiades, T. P., and the Queens University Plasmapharesis Study Group, 1983, Plasmapharesis in rheumatoid arthritis. A double-blind cross over trial, N. Engl. J. Med. 308:1124–1129.PubMedCrossRefGoogle Scholar
  34. Ellman, P., and Ball, R. E., 1948, Rheumatoid disease with joint and pulmonary manifestations, Br. J.Med. J. 2:816–820.CrossRefGoogle Scholar
  35. Fan, P. T., Davis, J. A., Somer, T., Kaplan, L., and Bluestone, R., 1980, A clinical approach to systemic vasculitis, Semin. Arthritis Rheum. 9:248–304.PubMedCrossRefGoogle Scholar
  36. Fauci, A. S., 1978, The spectrum of vasculitis, Ann. Intern. Med. 89:660–676.PubMedCrossRefGoogle Scholar
  37. Fauci, A. S., 1985, Cytotoxic and other regulatory agents, in: Textbook of Rheumatology, 2nd edition (W. N. Kelley, E. D. Harris, Jr., S. Ruddy, and C. B. Sledge, eds.), W. B. Saunders, Philadelphia, pp. 833–857.Google Scholar
  38. Fauci, A. S., and Wolff, S. M., 1973, Wegener’s granulomatosis: Studies in eighteen patients and a review of the literature, Medicine (Baltimore) 52:535–561.CrossRefGoogle Scholar
  39. Fauci, A. S., Dale, D. C., and Balow, J. E., 1976, Glucocorticoid therapy: Mechanisms of action and clinical considerations, Ann. Intern. Med. 84:304–315.PubMedCrossRefGoogle Scholar
  40. Fauci, A. S., Katz, P., Haynes, B. E., and Wolff, S. M., 1979, Cyclophosphamide therapy of severe systemic necrotizing vasculitis, N. Eng. J. Med. 301:235–238.CrossRefGoogle Scholar
  41. Fauci, A. S., Haynes, B. E., Katz, P., and Wolff, S. M., 1983, Wegener’s granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years, Ann. Intern. Med. 98:76–85.PubMedCrossRefGoogle Scholar
  42. Finan, M. C., and Winkelmann, R. K., 1983, The cutaneous extravascular necrotizing granuioma (Churg-Strauss granuloma) and systemic disease: A review of 27 cases, Medicine (Baltimore) 62:142–158.Google Scholar
  43. Frohnert, P. P., and Sheps, S. G., 1967, Long-term follow-up study of periarteritis nodosa, Am. J. Med. 43:8–14.PubMedCrossRefGoogle Scholar
  44. Furusho, K., Kamiya, T., Nakano, H., Kiyosawa, N., Shinomiya, K., Hayashidera, T., Tamura, T., Hirose, Q, Manabe, Y., Yokoyama, T., Kawarano, M., Baba, K., Baba, K., and Mori, C., 1984, High dose intravenous gamma globulin for Kawasaki disease, Lancet 2:1055–1088.PubMedCrossRefGoogle Scholar
  45. Godman, G. C., and Churg, J., 1954, Wegener’s granulomatosis: Pathology and review of the literature, A.M.A. Arch. Pathol 58:533–553.Google Scholar
  46. Goldman, J. A., Casey, H. L., McIIwain, H., Kirby, J., Wilson, C. H., Jr., and Miller, S. B., 1979, Limited plasmapharesis in rheumatoid arthritis with vasculitis, Arthritis Rheum. 22:1146–1150.PubMedCrossRefGoogle Scholar
  47. Goodman, B. W., Jr., 1979, Temporal arteritis, Am. J. Med. 67:839–852.PubMedCrossRefGoogle Scholar
  48. Gremmel, E., Druml, W., Schmidt, P., and Graninger, W., 1988, Cyclosporin in Wegener’s granulomatosis, Ann. Intern. Med. 108:491.PubMedCrossRefGoogle Scholar
  49. Guillevin, L., Le, T. H. D, Godeau, P., Jais, P., and Wechsler, B., 1988, Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: A study in 165 patients, Br. J. Rheumatol 27:258–264.PubMedCrossRefGoogle Scholar
  50. Hall, N. D., Bird, H. A., Ring, E. F. J., and Bacon, P. A., 1979, A combined clinical and immunological assessment of four cyclophosphamide regimes in rheumatoid arthritis, Agents Actions 9:97–102.PubMedCrossRefGoogle Scholar
  51. Hall, S., Barr, W., Lie, J. T., Stanton, A. W., Kazmier, F. J., and Hunder, G. G., 1985, Takayasu arteritis: A study of 32 North American patients, Medicine (Baltimore) 64:89–99.Google Scholar
  52. Hind, C. R. K., Paraskevakou, H., Lockwood, C. M., Evans, D. J., Peters, D. K., and Rees, A. J., 1983, Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis, Lancet 1:263–265.PubMedCrossRefGoogle Scholar
  53. Hutchinson, J., 1890, Diseases of the arteries: On a peculiar form of thrombotic arteritis of the aged which is sometimes productive of gangrene, Arch. Surg. 1:323–329.Google Scholar
  54. Inada, K., 1977, Aortitis syndrome, in: Vascular Lesions of Collagen Disease and Related Disorders (Y. Shiokawa, ed.), University Park Press, Baltimore, pp. 143–148.Google Scholar
  55. Kahan, B. D., 1989, Cyclosporine, N. Engl J. Ued. 321:1725–1738.CrossRefGoogle Scholar
  56. Kahn, M. F., Bedoiseau, M., and deSeze, S., 1967, Immunosuppressive drugs in the management of malignant and severe rheumatoid arthritis, Proc. R. Soc. Med. 60:130–133.PubMedGoogle Scholar
  57. Kawasaki, T., 1967, Mucocutaneous lymph node syndrome—clinical observation of 50 cases, Jap. J. Allergy 16:178–222.PubMedGoogle Scholar
  58. Kawasaki, T., Kosaki, E., Okawa, S., Shigematsu, I., and Yanagawa, H., 1974, A new infantile acute febrile mucocutaneous lymph node syndrome (MCNS) prevailing in Japan, Pediatrics 54:271–276.PubMedGoogle Scholar
  59. Kemper, J. W., Baggenstoss, A. H., and Slocumb C. H., 1957, The relationship of therapy with cortisone to the incidence of vascular lesions in rheumatoid arthritis, Ann. Intern. Med. 46:831–851.PubMedCrossRefGoogle Scholar
  60. Kulka, J. P., 1959, The vascular lesions associated with rheumatoid arthritis, Bull. Rheum. Dis. 10:201–202.PubMedGoogle Scholar
  61. Kusakawa, S., 1983, Long-term administrative care of Kawasaki disease, Acta Paediatr. Japan (Overseas Ed.) 25:205–209.CrossRefGoogle Scholar
  62. Kussmaul, A., and Maier, R., 1866, Uber eine bisher nicht beschreibene eigenthumliche Arteriener Krankung (periarteritis nodosa). Die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellahmung einhergeht, Deutsches Arch. Klin. Med. 1:484–517.Google Scholar
  63. Lanham, J. G., Elkon, K. B., Pusey, C. D., and Hughes, G. R. V, 1984, Systemic vasculitis in asthma and eosinophilia: A clinical approach to the Churg-Strauss syndrome, Medicine (Baltimore) 63:65–81.Google Scholar
  64. Leib, E. S., Restivo, C., and Paulus, H. E., 1979, Immunosuppressive and corticosteroid therapy of periarteritis nodosa, Am. J. Med. 67:941–947.PubMedCrossRefGoogle Scholar
  65. Leung, D., Cotran, R. S., Kurt-Jones, E., Burns, J. C., Newburger, J. W., and Pober, J. S., 1989, Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease, Lancet 2:1298–1302.PubMedCrossRefGoogle Scholar
  66. Levy, J., Barnett, E. V, MacDonald, N. S., Klinenburg, J. R., and Pearson, C. M., 1972, The effect of azathioprine on gammaglobulin synthesis in man, J. Clin. Invest. 51:2233–2238.PubMedCrossRefGoogle Scholar
  67. Lhote, E., Guillevin, L., Leon, A., Brissel, A., Luk, C., Sobel, A., and Simon, P., 1988, Complications of plasma exchange in the treatment of polyarteritis nodosa and Churg-Strauss angiitis and the contribution of adjuvant immunosuppressive therapy: A randomized trial in 72 patients, Artif. Organs 12:27–33.PubMedCrossRefGoogle Scholar
  68. Lockwood, C. M., Woolledge, S., Nicholas, A., Cotton, C., and Peters, D. K. 1979, Reversal of impaired spenic function of patients with nephritis or vasculitis (or both), N. Engl. J. Med. 300:524–530.PubMedCrossRefGoogle Scholar
  69. Masuda, K., Nakujima, A., Urayani, A., Naskae, K., Kogure, M., and Inaba, G., 1989, Double-masked trial of cyclosporin vs. colchicine and long-term open study of cyclosporin in Behçet’s disease, Lancet 1:1093–1096.PubMedCrossRefGoogle Scholar
  70. Mathieson, P. W., Cobbold, S. P., Hale, G., Clark, M. R., Oliviera, D. B. G., Lockwood, C. M., and Waldmann, H., 1990, Monoclonal antibody therapy in systemic vasculitis, N. Engl. J. Med. 323:250–254.PubMedCrossRefGoogle Scholar
  71. Mizushima, Y., Matsuda, T., Ohama, N., Hoshi, K., and Takeuchi, A., 1982, Colchicine and anti-thrombotic drugs in the treatment of Behçet’s disease, in: Behçet’s Disease: Pathogenetic Mechanisms and Clinical Future (G. Inaba, ed.), Japan Medical Research Foundation Publication No. 18, University of Tokyo Press, pp. 513-517.Google Scholar
  72. Nasu, T., 1977, Pathology of Takayasu’s truncoarteritis: A statistical observation of 76 autopsy cases in Japan, in: Vascular Lesions of Collagen Disease and Related Disorders (Y. Shiokawa, ed.), University Park Press, Baltimore, pp. 149–160.Google Scholar
  73. Newburger, J. W., Takahashi, M., Burns, J. C., Beiser, A. S., Chung, K. J., Duffy, C. E., Glode, M. P., Mason, W. H., Reddy, V, Sanders, S. P., Shulman, S. T., Wiggins, J. W., Hicks, R. V, Fulton, D. R., Lewis, A. B., Leung, D. Y. M., Colton, T., Rosen, F S., and Melish, M. E., 1986, The treatment of Kawasaki’s syndrome with intravenous gamma globulin, N. Engl. J. Med. 315:341–347.PubMedCrossRefGoogle Scholar
  74. Nicholls, A., Snaith, M. L., Maini, R. N., and Scott, J. T., 1973, Controlled trial of azathioprine in rheumatoid vasculitis, Ann. Rheum. Dis. 32:589–591.PubMedCrossRefGoogle Scholar
  75. Novack, S. NA., and Pearson, C. M., 1971, Cyclophosphamide therapy in Wegener’s granulomatosis, N. Engl J. Med. 284:938–942.PubMedCrossRefGoogle Scholar
  76. O’Duffy, J. D, Robertson, D. M., and Goldstein, N. P., 1984, Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet’s disease, Am. J. Med. 76:75–84.PubMedCrossRefGoogle Scholar
  77. Palmer, R. G., Dore, S., and Denman, A. M., 1986, Cyclophosphamide induces more chromosome damage than chlorambucil in patients with connective tissue diseases, Q. J. Med. 59:395–400.PubMedGoogle Scholar
  78. Palmer, R. G., Smith-Burchnell, C. A., Pelton, B. K., Hylton, W., and Denman, A. M., 1988, Use of T cell cloning to detect in vivo mutations induced by cyclophosphamide, Arthritis Rheum. 31:757–761.PubMedCrossRefGoogle Scholar
  79. Pickering, G., Bywaters, E. G. L., Danielli, J. F., Gell, P. G., Kellgren, J. H., Long, D. A., Neuberger, A., Nicholson, H., Prunty, F. T. G., Robb-Smith, A. H. T., Payling-Wright, G., Conybeare, E. T., and Duthie, J. J. R., 1960, Treatment of polyarteritis nodosa. Results after three years: Report to the Medical Research Council by the Collagen Disease and hypersensitivity panel, Br. Med. J. 1:1399–1400.CrossRefGoogle Scholar
  80. Rose, G. A., and Spencer, H., 1957, Polyarteritis nodosa, Q. J. Med. 26:43–81.PubMedGoogle Scholar
  81. Rosman, M., Bertino, J. R., 1973, Azathioprine, Ann. Intern. Med. 79:694–700.PubMedCrossRefGoogle Scholar
  82. Sack, M., Cassidy, J. T., and Bole, G., 1975, Prognostic factors in polyarteritis, J. Rheumatol 2:411–420.PubMedGoogle Scholar
  83. Savage, C. O., Winearls, C. G., Evans, D. J., Rees, A. J., and Lockwood, S. M., 1985, Microscopic polyarteritis: Presentation, pathology and prognosis, Q. J. Med. 56:467–483.PubMedGoogle Scholar
  84. Schein, P. S., and Winokur, S. T., 1975, Immunosuppressive and cytotoxic chemotherapy: Long-term complications, Ann. Intern. Med. 82:84–95.PubMedCrossRefGoogle Scholar
  85. Scott, D. G. I., 1988, Classification and treatment of systemic vasculitis, Br. J. Rheumatol 27:251–253.PubMedCrossRefGoogle Scholar
  86. Scott, G. D. I., and Bacon, P. A., 1984, Intravenous cyclophosphamide plus methylprednisolone in the treatment of systemic rheumatoid vasculitis, Am. J. Med. 76:377–384.PubMedCrossRefGoogle Scholar
  87. Scott, D. G. I., Bacon, P. A., Allen, C., Elson, C. J., and Wallington, T., 1981a, IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis: Comparative and serial studies during cytotoxic therapy, Clin. Exp. Immunol 43:54–56.PubMedGoogle Scholar
  88. Scott, D. G. I., Bacon, P. A., Bothamley, J. E., Allen, C., Elson, C. L., and Wallington, T. B., 1981b, Plasma exchange in rheumatoid vasculitis, J. Rheumatol 8:433–439.PubMedGoogle Scholar
  89. Scott, D. G. I., Bacon, P. A., and Tribe, C. R., 1981c, Systemic rheumatoid vasculitis: A clinical and laboratory study of 50 cases, Medicine (Baltimore) 60:288–297.Google Scholar
  90. Scott, D. G. I., Bacon, P. A., Elliott, P. J., Tribe, C. R., and Wallington, T. B., 1982, Systemic vasculitis in a district general hospital 1972–1980: Clinical and laboratory features, classification and prognosis of 80 cases, Q. J. Med. 51:292–311.PubMedGoogle Scholar
  91. Serra, A., Cameron, J. S., Turner, D. R., Hartley, B., Ogg, C. S., Neild, G. H., Williams, D. G., Taube, D., Brown, C. B., and Hicks, J. A., 1984, Vasculitis affecting the kidney: Presentation, histopathology and long-term outcome, Q. J. Med. 53: 181–207.PubMedGoogle Scholar
  92. Shelhamer, J. H., Volkman, D. J., Parnillo, J. E., Lawley, T. J., Johnston, M. M., and Fauci, A. S., 1985, Takayasu’s arteritis and its therapy, Ann. Intern. Med. 103:121–126.PubMedCrossRefGoogle Scholar
  93. Shimizu, T., 1977, Behçet’s disease: A systemic inflammatory disease, in: Vascular Lesions of Collagen Disease and Related Disorders (Y Shiokawa, ed.), University Park Press, Baltimore, pp. 201–211.Google Scholar
  94. Sigal, L., 1987, The neurologic presentation of vasculitic and rheumatological syndromes: A review, Medicine (Baltimore) 66: 157–179.Google Scholar
  95. Sokoloff, L., and Bunim, J. J., 1957, Vascular lesions in rheumatoid arteritis, J. Chronic Dis. 5:668–687.PubMedCrossRefGoogle Scholar
  96. Steinberg, A. D., Plotz, P. H., Wolff, S. M., Wong, V. G., Agus, S. G., and Decker, J. L., 1972, Cytotoxic drugs in treatment of non-malignant diseases, Ann. Intern. Med. 76:619–642.CrossRefGoogle Scholar
  97. Stillwell, T. J., Benson, R. C., Jr., deRemee, R. A., McDonald, T. J., and Weiland, L. H., 1988, Cyclophosphamide-induced bladder toxicity in Wegener’s granuiomatosis, Arthritis Rheum. 31:465–470.PubMedCrossRefGoogle Scholar
  98. Tabbara, K. K., 1983, Chlorambucil in Behçet’s: A reappraisal, Ophthalmobgy 90:906–908.Google Scholar
  99. Takayasu, M., 1908, A case with peculiar changes of the central retinal vessels, Acta Soc. Ophthalmol Japan 12:554.Google Scholar
  100. Vollertsen, R. S., Conn, D. L., Ballard, D. J., Ilstrup, D. M., Kazmar, R. E., Silverfield, J. C., 1986, Rheumatoid vasculitis: Survival and associated risk factors, Medicine (Baltimore) 65:365–375.Google Scholar
  101. Wallace, D., Goldfinger, D, Lowe, D, Brachman, M., and Klinenberg, J., 1981, A double blind controlled study of lymphapharesis in rheumatoid arthritis, Arthritis Rheum. 24:S125.Google Scholar
  102. Wegener, E., 1936, Uber generalisierte, septische Gefasserkrankungen, Verh. Dtsch. Ges. Pathol 29:202–209.Google Scholar
  103. Weisman, M., and Zvaiffler, N. J., 1975, Cryoglobulinaemia in rheumatoid arthritis. Significance in serum of patients with rheumatoid vasculitis, J. Clin. Invest. 56:725–739.PubMedCrossRefGoogle Scholar
  104. Wendling, D., Hory, B., and Blanc, D., 1985, Cyclosporine: A new adjuvant therapy for giant cell arteritis? Arthritis Rheum. 28:1078–1079.PubMedCrossRefGoogle Scholar
  105. West, B. C., Todd, J. R., and King, J. W., 1987, Wegener’s granuiomatosis and trimethoprim-sulphamethoxazole; Complete remission after a twenty-year course, Ann. Intern. Med. 106:840–842.PubMedCrossRefGoogle Scholar
  106. Wing, E. J., Burns, F. J., Fraley, D. S., Segel, D. P., and Adler, S., 1980, Infectious complications with plasmapharesis in rapidly progressive glomerulonephritis, J. Am. Med. Assoc. 244:2423–2426.CrossRefGoogle Scholar
  107. Wolff, S. M., Fauci, A. S., Horn, R. G., and Dale, D. C., 1974, Wegener’s granuiomatosis, Ann. Intern. Med. 81:513–525.PubMedCrossRefGoogle Scholar
  108. Woodworth, T. G., Abuelo, J. G., Austin, H. A., III, and Esparza, A., 1987, Severe glomerulonephritis with late emergence of classic Wegener’s granuiomatosis, Medicine (Baltimore) 66:181–191.Google Scholar
  109. Yazici, H., Pazarali, H., Barnes, C. G., Tuzun, Y., Ozyazgan, Y, Silman, A., Serdaroglu, S., Oguz, V., Yurdakul, S., Lovatt, G. E., Yazici, B., Somani, S., and Muftuoglu, A., 1990, A controlled trial of azathioprine in Behçet’s syndrome, N. Engl. J. Med. 322:281–285.PubMedCrossRefGoogle Scholar
  110. Yu, D. T., Clements, P. J., Peter, J. B., Levy, J., Paulus, H. E., and Barnett, E. V., 1974, Lymphocyte characteristics in rheumatic patients and response to therapy, Arthritis Rheum. 17:37–45.CrossRefGoogle Scholar
  111. Zeek, P. M., 1952, Periarteritis nodosa: A critical review, Am. J. Clin. Pathol 22:777–790.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • P. A. Bacon
    • 1
  • R. A. Luqmani
    • 1
  • D. G. I. Scott
    • 2
  • D. Adu
    • 3
  1. 1.Department of RheumatologyThe University of Birmingham, The Medical SchoolBirminghamEngland
  2. 2.Norfolk and Norwich HospitalNorfolk, NorwichEngland
  3. 3.Department of NephrologyQueen Elizabeth HospitalBirminghamEngland

Personalised recommendations